Early screening and diagnosis of chronic kidney disease
This study is testing different ways to spot chronic kidney disease early in adults, especially in the Chinese population, by looking at urine tests over three months to find the best screening methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT02841371 on ClinicalTrials.gov |
What this trial studies
This study focuses on the early detection and diagnosis of chronic kidney disease (CKD) in adults, particularly in the Chinese population. It aims to evaluate the albumin-creatinine ratio (ACR) through multiple tests over three months, alongside other urinary protein measurements, to determine the best screening methods for CKD. The study will also assess daily physiological variations in these measurements and establish reference values based on gender. By improving early diagnosis, the study seeks to address the significant public health issue posed by CKD.
Who should consider this trial
Good fit: Ideal candidates for this study are adults undergoing health examinations at the nephrology department who have chronic kidney disease.
Not a fit: Patients with severe heart failure, acute renal failure, or those with certain medical conditions or treatments that could interfere with the study will not benefit.
Why it matters
Potential benefit: If successful, this study could lead to improved early diagnosis and management of chronic kidney disease, potentially reducing adverse health outcomes.
How similar studies have performed: Other studies have shown success in using similar approaches for early detection of chronic kidney disease, indicating that this methodology is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Health examination population at the department of nephrology * Chronic kidney disease Exclusion Criteria: * Severe heart failure * Acute renal failure * Pleural or abdominal effusion * Serious edema or malnutrition * Skeletal muscle atrophy * Amputation * Ketoacidosis * Patients who were taking trimethoprim or cimetidine or angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB) * Patients who had recently received glucocorticoid and hemodialysis therapy * Female during the menstrual period * Pregnant woman * Who unable to sign informed consent
Where this trial is running
Nanjing, Jiangsu
- Nanjing First Hospital, Nanjing Medical University — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Xin Du — Nanjing First Hospital, Nanjing Medical University
- Study coordinator: Xin Du, MD
- Email: duxin168@163.com
- Phone: 86-025-87726209
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.